LifeTech Scientific Corporation
SZSC:1302 Stock Report
LifeTech Scientific Balance Sheet Health
Financial Health criteria checks 6/6 LifeTech Scientific has a total shareholder equity of CN¥3.4B and total debt of CN¥99.0M, which brings its debt-to-equity ratio to 2.9%. Its total assets and total liabilities are CN¥4.8B and CN¥1.4B respectively. LifeTech Scientific's EBIT is CN¥262.5M making its interest coverage ratio -16. It has cash and short-term investments of CN¥1.0B.
Key information Interest coverage ratio -16x Cash CN¥1.04b Equity CN¥3.39b Total liabilities CN¥1.43b Total assets CN¥4.82b
Recent financial health updates
Show all updates
Investor sentiment improves as stock rises 33% Oct 30
Investor sentiment deteriorates as stock falls 18% Oct 15
Investor sentiment improves as stock rises 18% Sep 30
First half 2024 earnings released: EPS: CN¥0.046 (vs CN¥0.049 in 1H 2023) Sep 02
LifeTech Scientific Corporation to Report First Half, 2024 Results on Aug 30, 2024 Aug 12
LifeTech Scientific Corporation Announces One-Year Follow-Up Results of Phase II Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System May 16
LifeTech Scientific Corporation, Annual General Meeting, May 27, 2024 Mar 29
Full year 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.077 in FY 2022) Mar 29
LifeTech Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 06
First half 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 in 1H 2022) Sep 01
Epione Surgical Navigation System Obtained Official Registration Approval by the China NMPA Aug 22
LifeTech Scientific Corporation to Report First Half, 2023 Results on Aug 30, 2023 Aug 11
Lifetech Scientific Corporation Announces Enrollment in the Phase Iii Clinical Study of Ibs®? Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed Jul 11
Full year 2022 earnings released: EPS: CN¥0.077 (vs CN¥0.068 in FY 2021) Mar 30
Investor sentiment improved over the past week Jan 16
LifeTech Scientific Corporation Announces Enrollment in the China Randomized Controlled Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed Dec 14
Insufficient new directors Nov 16
LifeTech Scientific Corporation Announces FDA Approval Investigator-Initiated Pre-Market Clinical Trial of Lambre Plus Laa Closure System Obtained Medical Insurance Coverage in the US Sep 05
First half 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.047 in 1H 2021) Aug 31
LifeTech Scientific Corporation to Report Q2, 2022 Results on Aug 30, 2022 Aug 13
Full year 2021 earnings released: EPS: CN¥0.068 (vs CN¥0.05 in FY 2020) Apr 27
Insufficient new directors Apr 27
Full year 2021 earnings released: EPS: CN¥0.068 (vs CN¥0.05 in FY 2020) Apr 01
LifeTech Scientific Corporation, Annual General Meeting, May 27, 2022 Mar 31
Insufficient new directors Mar 22
Investor sentiment improved over the past week Nov 30
Lifetech Scientific Corporation Announces YuranosTM Abdominal Aortic Stent Graft System Obtained Registration Approval from the China NMPA Nov 25
First half 2021 earnings released: EPS CN¥0.047 (vs CN¥0.023 in 1H 2020) Sep 02
Investor sentiment deteriorated over the past week Jul 27
LifeTech Scientific Corporation Announces Grant of Medical Device Registration Certificate in Malaysia for Its Self-Developed Ibs Angeltm Iron Bioresorbable Scaffold System Jun 10
Investor sentiment improved over the past week Apr 24
Non-Executive Director has left the company Apr 21
Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019) Apr 18
Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019) Mar 31
LifeTech Scientific Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021 Mar 12
New 90-day low: HK$3.62 Mar 05
Lifetech Scientific Corporation Announces Admission to Special Examination and Approval Procedure for Innovative Medical Devices in Respect of Artery Stent Graft System Jan 28
New 90-day high: HK$5.46 Jan 22
New 90-day high: HK$4.43 Dec 30
Market bids up stock over the past week Nov 25
Gl Trade Investment III L.P. and Gao Ling Fund, L.P., a fund managed by Hillhouse Capital Management, Ltd. acquired 10.67% stake in LifeTech Scientific Corporation (SEHK:1302) from Central Huijin Investment Ltd. Nov 25
Market bids up stock over the past week Nov 20
New 90-day high: HK$2.99 Nov 20
New 90-day low: HK$2.05 Sep 21
First half earnings released Aug 30
LifeTech Scientific Corporation to Report First Half, 2020 Results on Aug 28, 2020 Aug 15
Financial Position Analysis
Short Term Liabilities: 1302's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥826.5M).
Long Term Liabilities: 1302's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥602.8M).
Debt to Equity History and Analysis
Debt Level: 1302 has more cash than its total debt.
Reducing Debt: 1302's debt to equity ratio has reduced from 22.7% to 2.9% over the past 5 years.
Debt Coverage: 1302's debt is well covered by operating cash flow (300.6%).
Interest Coverage: 1302 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}